ArticleCancer biology & therapy2011
Novel surface targets and serum biomarkers from the ovarian cancer vasculature.
Article in Cancer biology & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- ADAM12 in a stromal-checkpoint framework: integrating tumor microenvironment remodeling and therapy resistance in solid tumors.Cell communication and signaling : CCS · 2026Review
- A Structural and Functional Perspective of Death Receptor 6.Frontiers in pharmacology · 2022Review
- A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying HenComparative medicine · 2021Review
- Comprehensive Analysis and Identification of Prognostic Biomarkers and Therapeutic Targets Among FAM83 Family Members for Gastric Cancer.Frontiers in cell and developmental biology · 2021Article
- Article
- miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis.Cell death & disease · 2020Article
- FAM83H is involved in stabilization of β-catenin and progression of osteosarcomas.Journal of experimental & clinical cancer research : CR · 2019Article
- Serum biomarker panels for the diagnosis of gastric cancer.Cancer medicine · 2019Article
- Death receptor 6 promotes ovarian cancer cell migration through KIF11.FEBS open bio · 2018Article
- ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.Molecular cancer research : MCR · 2017Article
- FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC.Scientific reports · 2017Article
- Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.Oncotarget · 2016Article
- Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-κB, P38 MAPK and STAT3 pathways.Oncogenesis · 2016Article
- Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model.Journal of immunology research · 2016Article
- ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.Carcinogenesis · 2015Article
- Identification of novel vascular targets in lung cancer.British journal of cancer · 2015Article
- T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.Cancer immunology research · 2015Article
- Vascular marker expression during the development of various types of gynaecological malignancy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Identification of a Peptide fromJournal of molecular biomarkers & diagnosis · 2014Article
- Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.The Journal of clinical investigation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
The molecular phenotype of tumor vasculature is different from normal vasculature, offering new opportunities for diagnosis and therapy of cancer, but the identification of tumor-restricted targets remains a challenge. We investigated 13 tumor vascular markers (TVMs) from 50 candidates identified through expression profiling of ovarian cancer vascular cells and selected to be either transmembrane or secreted, and to be either absent or expressed at low levels in normal tissues while overexpressed in tumors, based on analysis of 1,110 normal and tumor tissues from publicly available Affymetrix microarray data. Tumor-specific expression of each TVM was confirmed at the protein level in tumor tissue and/or in serum. Among the 13 TVMs, 11 were expressed on tumor vascular endothelium; the remaining 2 TVMs were expressed by tumor leukocytes. Our results demonstrate that certain transmembrane TVMs such as ADAM12 and CDCP1 are selectively expressed in tumor vasculature and represent promising targets for vascular imaging or anti-vascular therapy of epithelial ovarian cancer, while secreted or shed molecules such as TNFRSF21/DR6 can function as serum biomarkers. We have identified novel tumor-specific vasculature markers which appear promising for cancer serum diagnostics, molecular imaging and/or therapeutic targeting applications and warrant further clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.